stockrow
Saturday 7 November 2026
Export CRMD’s income statement to Excel — free account
CorMedix Inc
CRMD Healthcare Biotechnology
CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024.
- Revenue
- +156.5%
- EPS
- +13.8%
- Free cash flow
- +185.9%
Quarter to June 2026, against a year earlier
5.30
0.07
+1.34%
Follow CRMD
Alert me
CorMedix Inc (CRMD) P/E ratio
As of 6 November 2026, CorMedix Inc (CRMD) trades at a P/E ratio of 2.2×. Over the past ten years it has ranged from 0.0× (March 2025) to 69.0× (June 2025); the current reading is higher than 86% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 5.3× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 3.3× | 13.69% |
| Mar 2026 | 2.9× | (45.56%) |
| Dec 2025 | 5.3× | 1.81% |
| Sep 2025 | 5.2× | (67.27%) |
| 37 more quarters | Free account |
Against its own ten years
Low 0.0×
High 69.0×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| EDIT Editas Medicine, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| OCS Oculis Holding AG compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | n/m |
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| CRMD CorMedix Inc | 2.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)